Manufacturers: Foresee Pharmaceuticals
FP-045 (mirivadelgat) is a highly selective oral small molecule allosteric activator of ALDH2, developed by Foresee Pharmaceuticals. It is being investigated in Phase 2 clinical trials for Parkinson's disease (SLEIPNIR platform trial) and pulmonary hypertension-interstitial lung disease (WINDWARD study).
FP-045 (mirivadelgat) is a highly selective oral small molecule allosteric activator of ALDH2, developed by Foresee Pharmaceuticals. It is being investigated in Phase 2 clinical trials for Parkinson's disease (SLEIPNIR platform trial) and pulmonary hypertension-interstitial lung disease (WINDWARD study).
Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme. It is designed to increase the activity of ALDH2, which directly clears toxic aldehydes from the brain. By supporting this natural defense system, mirivadelgat accelerates detoxification and could potentially slow the ongoing loss of nerve cells in neurodegenerative diseases such as Parkinson's disease.
Parkinson's disease: Phase 2a (SLEIPNIR platform trial, 40 participants, 12-week treatment, in collaboration with Haukeland University Hospital, funded by Cure Parkinson's). Pulmonary hypertension-interstitial lung disease (PH-ILD): Phase 2 (WINDWARD study, initiated Q2 2025).
2 associated conditions
